

# ANTIBODY DRUG CONJUGATION SERVICES



**Piramal**  
Pharma Solutions

Piramal is the world leader in delivering customer-centric solutions in the field of Antibody Drug Conjugates (ADCs) and Bioconjugates to global pharmaceutical companies. Our world-class facilities in the UK & US, backed by a highly experienced team, offer integrated services, from Conjugation Development to Clinical & Commercial ADC GMP Batch Manufacturing & Fill/Finish.

---

## OUR UNIQUE POSITION INCLUDES:

- Integrated service, from Preclinical Development of Conjugated ADC to Sterile Fill/Finish
- >98% GMP Batch success rate
- Global supplier for commercial ADCs
- GMP Manufacture - 600+ batches, 40 bioconjugate entities. Early Phase to commercial. 10+ year commercial manufacture experience.
- Development lab - 500+ batches, 200+ bioconjugate entities.
- Worked with over 60 different Toxin/Toxin-Linker Systems
- Successfully audited by US FDA, UK MHRA, Japan PMDA, Brazil ANVISA & Turkey Ministry of Health

---

## OUR BIOCONJUGATION SERVICES

Piramal offers an end-to-end service, from Conjugation Development through Clinical Trials Supply, to Commercial Manufacture.

Specific service areas include:

- Proof-of-Concept Preclinical Development Studies
- Bioconjugation Process Development & Scale-Up
- ADC/ Bioconjugates Clinical Manufacturing
- Commercial Manufacturing
- ADC/ Bioconjugates Fill/Finish
- Analytical Development Services
- Toxicology, Bulk Drug Substance and Finished Drug Product release testing
- ICH Stability testing



---

## OUR TEAM

People are our biggest asset. Our technical knowledge is what separates us from the pack. We believe that our service is world-class because of our people. Currently, we have a team of over 180 split across our Development, Quality & Manufacturing services functions.

- Technical knowledge
- Empowering creative thought
- Consistent in our thought
- Protecting & enhancing
- Aspiring to be the best
- Striving to be humble

Our R&D team includes world experts in Process Development, Scale-up & Analytical Development, including Cell-killing Assays. Our GMP Manufacturing experience is unparalleled & backed by a strong Quality Assurance Team. Whilst being supported by a global parent company, our ADC services site in Grangemouth maintains that personal touch for our clients, providing tailored client-centric solutions for their projects.

---

## PROOF OF CONCEPT

Cost-effective Proof of Concept Conjugation service to demonstrate the viability of Cytotoxic Drugs or Monoclonal Antibodies for use in Therapeutic ADCs. ADC Standards to benchmark client materials.

---

## TAILORED TO YOUR NEEDS

### Core strengths

- Short lead times to start your projects
- Competence to operate at mg-g scale for preparation of Low Endotoxin Conjugates
- Integrated Process & Analytical Development Functions
- Process development & scale up to GMP manufacture

### Client Antibodies for suitability for Conjugation

- Programmes tailored to meet your needs
- Comparison of different chemistries (Cysteine, Lysine)
- Range of different Linkers available (Cleavable, Non-cleavable, PEGylated)
- Range of Payloads available (Microtubule-disrupting Drugs, DNA Damaging Compounds, Experience with a range of non cytotoxic payloads)
- Preparation of different Drug Loadings
- Analytical Characterisation & Screening of Conjugates

### Client Cytotoxic or Linker Technologies

- Piramal can make various Conjugates with Model Antibodies using your Linker or Drug Platforms
- Experience with a range of Novel Linker Technologies



## ANALYTICAL SERVICES

Piramal provides on-site analytical services for ADC Characterisation. This includes Analytical Method Development & Validation, Method Transfer & Release/Stability Testing for Bulk Drug Substance & Finished Product.

ANALYTICAL CATEGORY	TYPICAL ASSAYS	
Identity	<ul style="list-style-type: none"> <li>✓ icIEF Profile</li> <li>✓ HIC Profile</li> </ul>	<ul style="list-style-type: none"> <li>✓ Dot Blot</li> <li>✓ ELISA</li> </ul>
Strength	<ul style="list-style-type: none"> <li>✓ Protein Concentration (UV / SEC / SoloVPE)</li> </ul>	
Potency	<ul style="list-style-type: none"> <li>✓ Drug Load</li> <li>✓ Binding ELISA</li> </ul>	<ul style="list-style-type: none"> <li>✓ Cell Based Assay</li> <li>✓ Effector Function Assays (ADCP / ADCC)</li> </ul>
Purity	<ul style="list-style-type: none"> <li>✓ SEC</li> <li>✓ CE-SDS (R and NR)</li> <li>✓ Charge Profile (cIEF / icIEF / CEX)</li> <li>✓ % Unconjugated Ab (HIC)</li> </ul>	<ul style="list-style-type: none"> <li>✓ Conjugate Distribution (HIC / PLRP)</li> <li>✓ Residual Solvent (LC or GC)</li> <li>✓ Residual Drug-related species</li> </ul>
Safety	<ul style="list-style-type: none"> <li>✓ Bioburden</li> </ul>	<ul style="list-style-type: none"> <li>✓ Endotoxin</li> </ul>
Quality	<ul style="list-style-type: none"> <li>✓ pH</li> <li>✓ Osmolality</li> </ul>	<ul style="list-style-type: none"> <li>✓ Appearance (Colour and Clarity)</li> <li>✓ Excipient Levels (Tween)</li> </ul>
Characterisation	<ul style="list-style-type: none"> <li>✓ Peptide Mapping (LC-MS)</li> <li>✓ Glycan Profiling (LC-MS / CE)</li> </ul>	<ul style="list-style-type: none"> <li>✓ Drug Distribution (LC-MS)</li> </ul>

### Drug Substance & Drug Product Stability Testing

- State-of-the-art Onsite Analytical Development & Quality Control Laboratories
- Full testing to ICH Guidelines
- Over 80 stability trials conducted for Clinical & Commercial ADC Batches

## STATE-OF-THE-ART DEVELOPMENT

### Cell-based Assay (CBA) experience

- World leader in the development of Cell-killing Assays
- Tailored development programmes utilising Design of Experiment Approaches
- Experience in Technical Transfer/Optimisation of client methods
- Multiple CKAs Developed & Validated to meet client & regulatory requirements
- Expert knowledge of Validation to Regulatory Standards <USP111>, <1032, <1033> & PhEur 5.3
- Development of Characterisation methods



## ADC MANUFACTURING

Multi-product facility for Clinical & Commercial Manufacturing of Antibody Drug Conjugates (ADCs). Process Development, Characterisation, Optimisation & Scale-up expertise supporting successful GMP Manufacturing.

### Core strengths

- Fully licenced by MHRA
- Approved for Commercial ADC Supply by FDA & other worldwide authorities
- >98% GMP Batch success rate
- Over 30 years experience of working safely with High Potency Materials
- Over 15 years experience of working safely with ADCs & Potent Payloads
- Batch sizes up to 2.5 kg input mAb
- Up to 1000L Reactive Volume Capability depending on the complexity
- Three ADC manufacturing suites based on Isolator Technology
- Two commercial-scale manufacturing suites
- Dedicated or single-use Product-contact Manufacturing Components
- 100% Batch Shipping success rate

### Unparalleled experience

- Over >1100 ADC/Bioconjugates batches manufactured
- Over >600 GMP batches manufactured
- Over 200 Different conjugates from 120 antibodies
- Over 60 different toxin/toxin-linker system
- Over 40 different ADCs manufactured to GMP
- Over >250 commercial batches manufactured



### Accelerated Phase I GMP Delivery of Antibody-Drug Conjugates

- Shortens timelines, because speed matters
- Solutions that are customized to the scope of your project
- Take advantage of our experience in ADC problem solving
- Includes first clinical supply of drug substance and drug product

### Construction of a multipurpose state-of-the-art Antibody-Drug Conjugate (ADC) manufacturing and aseptic fill/finish facility in Grangemouth, Scotland

Two new ADC manufacturing suites, operational by Q3 2023, will be added to the existing three.



---

## GLOBAL SUPPLIES

### Supply Chain Management

- Well established relationship with World Courier or Pharmafreight
- Temperature Logging on all shipments
- Typically 2-3 days shipment time
- Shipping in small Insulated Boxes, Cryocontainers & Drums

---

## FILL/FINISH OF ADC

Piramal offers Aseptic Filling of ADC Drug Product through our FDA-approved state-of-the-art manufacturing facility in Lexington, KY. Our facility is centred around Mobile Isolator Technology, providing an ISO 5 environment during processing, as well as Product Containment for Potent & Cytotoxic Products.

### Aseptic filling capabilities include:

- Pre-formulation & Formulation of Liquid & Lyophilised Drug Products
- Liquid & Lyophilised Drug Product Manufacturing
- Vial sizes from 2-50ml
- Dispensing volumes from 0.5ml to 50ml
- Batch sizes up to 50,000 vials, for Liquid-filled Products (size dependent)
- Batch sizes up to 15,000 vials, for Lyophilised Products (size dependent)



---

## PROJECT MANAGEMENT

Piramal prides itself in its world-class project management, designed in partnership with its clients.


- Virtual extension of your company
- Flexible & tailored to meet clients' needs
- Single point of contact to champion your project
- Project management ensures continuity for entire program of activities & remains with projects from Technology Transfer to GMP Manufacture





## OUR GLOBAL PRESENCE

- 1 RIVERVIEW, USA**  
HPAPI Development & Manufacturing  
USFDA, PMDA
- 2 SELLERSVILLE, USA**  
Formulation Development & Manufacturing  
USFDA, EMA
- 3 LEXINGTON, USA**  
Sterile Development & Manufacturing  
USFDA, PMDA
- 4 GRANGEMOUTH, UK**  
ADC Development & Manufacturing  
USFDA, MHRA
- 5 MORPETH, UK**  
API & Formulation Development & Manufacturing  
USFDA, MHRA
- 6 AURORA, CANADA**  
API Development & Manufacturing  
USFDA, PMDA
- 7 DIGWAL, INDIA**  
API Development & Manufacturing  
USFDA, MHRA
- 8 TURBHE, INDIA**  
Peptide API Development & Manufacturing  
USFDA



**SHANGHAI, CHINA**  
• Sourcing Office

- 9 ENNORE, INDIA**  
API Development & Manufacturing  
WHO-GMP
- 10 AHMEDABAD - PDS, INDIA**  
Drug Discovery
- 11 PITHAMPUR, INDIA**  
Formulation Manufacturing  
USFDA, EU Finland, ANVISA
- 12 AHMEDABAD - PPDS, INDIA**  
Formulation Development  
EU Finland
- 13 MAHAD, INDIA\***  
Vitamins & Minerals Premixes  
USFDA, WHO-GMP
- 14 RABALE, INDIA**  
API Development
- 15 HYDERABAD, INDIA\*\***  
Vaccines & Biologics Process Development & Manufacturing

Note: \*Dietary Ingredients  
\*\*Through PPS Minority Investment in Yapan Bio

